ELCC 2016 | Characterizing tumor-infiltrating lymphocytes in resectable early stage NSCLC
David Carbone
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses the characterization of tumor-infiltrating lymphocytes in resectable early stage non-small cell lung cancer (NSCLC) and the application of this understanding for the development of immunotherapy in early stage disease.
Related videos
0:48 The LUNAR study: TTFields for NSCLC
Ori Farber
0:55 Tumor treating fields as an anti-mitotic therapy
Ori Farber
0:48 Patient impact: development of drugs to treat METex14 alterations
Paul Paik
1:04 Tepotinib: advanced non-small cell lung cancer
Paul Paik
0:53 Future treatment options for squamous cell lung cancer
Paul Paik
